PMM2-CDG
PMM2-CDG is a rare genetic disorder that affects the body's ability to process sugars, leading to a range of symptoms including developmental delays, neurological issues, and problems with organ function.
GLM101 for PMM2-CDG: Safety and Effects
We are studying the safety of GLM101 in patients with PMM2-CDG who have previously received the treatment. We will also look at its impact on coordination, balance, and sugar levels.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 2 and 65 years old?
- Do you have a confirmed diagnosis of PMM2-CDG (a specific genetic condition)?
- Are you currently pregnant or breastfeeding?
- Have you had a history of drug or alcohol use disorder in the past year?
- Does your weight exceed 75 kg?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Glm101
Alfa-D-Mannopyranosyl Phosphate Dipotassium
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Sant Joan De Deu Barcelona Hospital
Pediatric Neurology Department
Esplugues de Llobregat, Spain
Sponsor: Glycomine Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.